DACS
LEGN icon

Dymon Asia Capital (Singapore)’s Legend Biotech LEGN Stock Holding History

Dymon Asia Capital (Singapore)’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-12,000
Closed -$585K – 126
2024
Q3 		$585K Buy
+12,000
New +$639K 0.16% 72

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Dymon Asia Capital (Singapore)'s LEGN Position: Q4 2024 in Review

Dymon Asia Capital (Singapore) sold out of Legend Biotech (LEGN) in Q4 2024, closing a stake of 12,000 shares — an estimated $585K sold.

Dymon Asia Capital (Singapore) first reported a position in LEGN in Q3 2024 and held it in 1 quarter. The position peaked at $585K in Q3 2024. 211 funds tracked by Wall St. Rank hold LEGN as of Q4 2024.

  • Dymon Asia Capital (Singapore) reported no remaining Legend Biotech position as of Q4 2024 after selling out during the quarter.
  • Dymon Asia Capital (Singapore) sold 12,000 Legend Biotech shares in Q4 2024, an estimated $585K.
  • Dymon Asia Capital (Singapore) first reported a position in Legend Biotech in Q3 2024 and held it in 1 quarter.
  • Dymon Asia Capital (Singapore)'s Legend Biotech position peaked at $585K in Q3 2024.
  • 211 funds tracked by Wall St. Rank held Legend Biotech as of Q4 2024.

Based on Dymon Asia Capital (Singapore)'s 13F filing for Q4 2024, filed 13 Feb 2025.